Gene Therapy Approaches

Gene Therapy Basics - Fixing Faulty Genes

• Definition: Therapeutic gene introduction into somatic cells to treat or cure genetic disorders.
• Goals:
  • Correct underlying genetic defect.
  • Provide cells with a new function.
• Types:
  • Somatic Cell Therapy: Targets non-reproductive cells; genetic changes are not inherited. Primary focus of current research.
  • Germline Therapy: Modifies sperm, eggs, or embryos; changes are heritable. Ethically banned in humans.

⭐ The first approved gene therapy trial targeted Adenosine Deaminase (ADA) deficiency in Severe Combined Immunodeficiency (SCID).

Delivery Systems - Gene Taxi Services

📌 Mnemonic for viral vectors: 'RALph Loves AAVenues' (Retrovirus, Adenovirus, Lentivirus, AAV).

Viral Vectors:

• Non-viral Methods: Generally safer, simpler to produce, and can carry larger genes, but often have lower transfection efficiency and transient expression compared to viral vectors.
  • Liposomes: Lipid vesicles encapsulate DNA/RNA, fusing with cell membrane for delivery. Pros: Low immunogenicity, large DNA capacity. Cons: Low efficiency, transient expression.
  • Electroporation: Brief electrical pulses create temporary pores in cell membranes for nucleic acid entry. Pros: Versatile for many cell types. Cons: Cell toxicity, variable efficiency.
  • Gene Gun (Biolistics): DNA-coated heavy metal particles (e.g., gold) are propelled at high velocity into cells/tissues. Pros: Direct tissue penetration, useful for skin/muscle. Cons: Superficial delivery, potential cell damage.
  • Nanoparticles (e.g., polymeric, lipid-based): Synthetic carriers encapsulate nucleic acids, protecting them and facilitating cell entry. Pros: Can be engineered for targeted delivery, improved stability. Cons: Potential toxicity, variable in vivo efficiency.

⭐ Adeno-Associated Viruses (AAVs) are widely used for in vivo gene therapy due to their low immunogenicity and ability to transduce non-dividing cells.

Therapeutic Strategies - Molecular Toolkits

• Gene Augmentation Therapy:
  • Adds functional gene copy for loss-of-function disorders.
  • Example: ADA gene for Severe Combined Immunodeficiency (SCID).
• Gene Inhibition/Silencing:
  • Reduces expression of detrimental genes (e.g., dominant-negative mutations, viral genes).
  • Tools: Antisense oligonucleotides (ASOs), siRNA, shRNA, ribozymes.
• Targeted Gene Mutation Correction (Gene Editing):
  • Precise DNA modification at specific loci.
  • Tools:
    • CRISPR-Cas9 (RNA-guided endonuclease)
    • Zinc Finger Nucleases (ZFNs)
    • TALENs
• Cell-Based Gene Therapy:
  • Modification of patient's or donor cells ex vivo or in vivo.
  • Example: CAR T-cell therapy for cancer.

⭐ CRISPR-Cas9 system offers a versatile and relatively simple method for targeted genome editing, revolutionizing gene therapy research.

Clinical Landscape - Successes & Hurdles

• Approved Therapies & Diseases:
  • Zolgensma® (onasemnogene abeparvovec): Spinal Muscular Atrophy (SMA)
  • Luxturna® (voretigene neparvovec): Leber's Congenital Amaurosis (LCA)
  • Kymriah®/Yescarta® (CAR T-cells): B-cell malignancies
  • Strimvelis®/Libmeldy®: ADA-SCID/Metachromatic Leukodystrophy (MLD)
• Major Hurdles:
  • Immunological reactions (vector/transgene product)
  • Insertional mutagenesis (integrating vectors)
  • Off-target effects (gene editing)
  • Long-term efficacy & safety
  • High cost

  ⭐ The high cost of gene therapies like Zolgensma (>$2 million) poses significant challenges for patient access and healthcare systems.

• ELSI (Ethical, Legal, Social Implications):
  • Somatic vs. germline editing
  • Therapy vs. enhancement
  • Accessibility & affordability

High‑Yield Points - ⚡ Biggest Takeaways

• Gene therapy aims to correct genetic defects by introducing functional genes into cells.
• Viral vectors like retroviruses, adenoviruses, and AAV are common for efficient gene delivery.
• SCID (Severe Combined Immunodeficiency) was one of the first diseases successfully treated using gene therapy.
• Somatic cell gene therapy targets non-reproductive cells; germline therapy alters the gene pool and is controversial.
• CRISPR-Cas9 technology offers highly precise genome editing capabilities for therapeutic applications.